Na-Phenylbutyrate VAscular Trial

Launched by UNIVERSITY OF PENNSYLVANIA · Oct 14, 2024

Keywords

ClinConnect Summary

The Na-Phenylbutyrate VAscular Trial is a study aimed at understanding how the drug sodium phenylbutyrate (NaPB) affects blood pressure and blood vessel function in both healthy individuals and those with diabetes. This trial is in the early stages and is not yet recruiting participants. The study will include adults aged 18 to 60, so if you're over 60 or under 18, you won’t be eligible to participate. Healthy volunteers must not have any history of diabetes, while those with diabetes can participate whether or not they require insulin.

If you join this trial, you’ll need to be able to give your written consent and follow the study procedures. Unfortunately, people with certain health conditions, like high blood pressure or serious heart or kidney problems, or those who are pregnant or have recently used tobacco or drugs, cannot participate. This study is an important step in exploring new treatments for diabetes and may contribute to better understanding how to manage blood pressure and vascular health in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over 18 years of age and less than 60.
• • Healthy subjects will have no history of diabetes or prediabetes.
• • Diabetes subjects can be either insulin dependent or not.
• • Able to provide written consent and to comply with the procedures of the study protocol.
• Exclusion Criteria:
• • Age \<18 or \>60
• • Pregnant or lactating women.
• • Subjects with hypertension or taking any vasodilatory medications, any steroidal drugs, haloperidol, or valproic acid.
• • Patients with congestive heart failure, severe renal insufficiency, hepatic failure, or known sodium retention with oedema.
• • Active alcohol or substance abuse.
• • Use of tobacco within the previous six months.
• • Unble to provide written consent and to comply with the procedures of the study protocol.